Visterra

Acquired

Bringing better biologics to life.

Cambridge, United States · Founded 2007 · $116.1M raised

Employees
51–200
Founded
2007
Business Model
B2B
Total Funding
$116.1M
Last Round
$23.6M Series COct 2017
Rounds
7
Acquisition Date
Jul 2018

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Visterra is a biologics research and early-stage clinical development company focused on developing novel therapeutics for patients with immune-mediated and other hard-to-treat diseases. The company applies cutting-edge computational, AI, and experimental research methods alongside agile preclinical development to engineer next-generation antibody-based therapies. Visterra's lead program, sibeprenlimab (VIS171), targets IgA nephropathy (IgAN) and has received FDA acceptance and Priority Review designation. The company leverages a unique platform combining structural biology, computational design, and proprietary antibody engineering to develop differentiated biologics. Originally spun out of MIT, Visterra was founded in 2007 and is based in Cambridge, Massachusetts. The company was acquired by Otsuka Holdings, which continues to advance its clinical pipeline.

Summary

Visterra is a Biotech company based in Cambridge, United States, founded in 2007. It has raised $116.1M in total across 7 rounds, most recently a $23.6M Series C round in Oct 2017. Investors include Otsuka Pharmaceutical, Polaris Partners and Vertex Venture Holdings.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionJul 2018

Sign up to see all 8 events

Funding: Seed through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Visterra on Indexed.vc
<a href="https://indexed.vc/companies/visterra"><img src="https://indexed.vc/api/badge/company/visterra" alt="Visterra on Indexed.vc" width="260" height="76" /></a>